Medicare Reveals 44% Lower Prices For 15 Drugs In 2nd Round Of Negotiations [Forbes]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Forbes
Negotiations led by the Centers for Medicare and Medicaid Services resulted in 44% lower net prices than health plans participating in Medicare's outpatient pharmacy benefit program (Part D) were paying in 2024. Additionally, this figure is twice as large as the 22% achieved during the first round of negotiations. The 15 selected drugs accounted for $42.5 billion in total Part D gross prescription drug spending last year. Medicare beneficiaries spent $1.7 billion out of pocket on these medications. The negotiated price reductions are projected to save beneficiaries an estimated $685 million in out-of-pocket costs. The so-called maximum fair prices are the result of a drug pricing provision that was enacted in 2022 under the Inflation Reduction Act. To be eligible to be selected for price negotiation, small molecule drugs must be at least seven years post launch and not face “bona fide” generic competition, and large molecule biologics must be 11 years post launch and not have bona
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Hims and Hers acquires Livewell ahead of generic Ozempic launch in Canada [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk A/S (NYSE:NVO) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer's, despite trial setback [MSNBC.com]MSNBC.com
- Novo Nordisk A/S (NVO): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website